Intravacc launches phase I clinical trial of Avacc 10®, an intranasal subunit booster vaccine for SARS-CoV-2

Intravacc launches phase I clinical trial of Avacc 10®, an intranasal subunit booster vaccine for SARS-CoV-2 Bilthoven, The Netherlands, 30 November 2022 –  Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced that it enrolled the first participant  in a phase I first in-human clinical trial of Avacc…

CEPI partners with Intravacc to develop an intranasal, broadly protective Betacoronavirus vaccine

CEPI partners with Intravacc to develop an intranasal, broadly protective Betacoronavirus vaccinee Bilthoven, The Netherlands, 6 October 2022 –  CEPI, the Coalition for Epidemic Preparedness Innovations, and Dutch vaccine clinical development and manufacturing organization Intravacc, today announced the latest funding award under CEPI’s US$200m programme to advance the development of vaccines that provide broad protection against SARS-CoV-2…

Intravacc awarded US$14.6 Million NIH/NIAID contract to develop Intranasal Gonorrhea vaccine

Intravacc awarded US$14.6 Million NIH/NIAID contract to develop intranasal gonorrhea vaccine Bilthoven, The Netherlands, 5 October 2022 –  Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced that it has been awarded a contract with base and options that may total US$14.6 million from the US National Institute…

Intravacc announces additional favorable preclinical and toxicology data for Avacc 10®, an intranasal SARS-CoV-2 candidate vaccine

Intravacc announces additional favorable preclinical and toxicology data for Avacc 10®, an intranasal SARS-CoV-2 candidate vaccine Bilthoven, the Netherlands, 12 September 2022 – Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced additional favorable preclinical and toxicology data for Avacc 10®, the company’s SARS-CoV-2 intranasal candidate vaccine. These results…